Article
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.
The Lancet. Infectious diseases - 1 Mar 2025
Fourati Slim, Reslan Alawiya, Bourret Jérome, Casalegno Jean-Sébastien, Rahou Yannis, Chollet Lionel, Pillet Sylvie, Tremeaux Pauline, Dossou Nefert Candace, Gault Elyanne, Salmona Maud, Imbert-Marcille Berthe-Marie, Mirand Audrey, Larrat Sylvie, Moisan Alice, Marot Stéphane, Schnuriger Aurélie, Veyrenche Nicolas, Engelmann Ilka, Handala Lynda, Henry Amandine, Stephan Valentin, Brichler Ségolène, Avettand-Fenoel Véronique, Zemali Nael, Lefeuvre Caroline, Pronier Charlotte, Deroche Luc, Jaffar-Bandjee Marie-Christine, Mouna Lina, Francois Catherine, Regueme Alexandre, Hartard Cédric, Rogez Sylvie, Gallais Floriane, Ly Arnaud, Rodriguez Christophe, Dos Santos Georges, Simon-Loriere Etienne, Schwartz Olivier, Buchrieser Julian, Pawlotsky Jean-MiIchel, Lemoine Frédéric, Audureau Etienne, Rameix-Welti Marie-Anne
Abstract excerpt
BACKGROUND: Nirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants. In France, more than 210 000 single doses were administered in infants younger than 1 year during the 2023-24 season. In this context, the selection and spread of escape variants might be a concern. Here, we aimed to characterise RSV associated with...
Read the complete abstract on PubMed